Skip to main content
Fig. 3 | BMC Pharmacology and Toxicology

Fig. 3

From: Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC

Fig. 3

OS trend in (a) patients with (n =30) or without (n =68) treatment-related cutaneous toxicity (p =0.0008); (b) patients with (n =27) or without (n =71) treatment-related gastrointestinal toxicity (p =0.5); (c) patients with (n =20) or without (n =78) treatment-related endocrinological toxicity (p =0.0005); and (d) patients with toxicity (n =75) or without toxicity (n =23) (p =0.006)

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us